Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
about
The rising challenge of non-AIDS-defining cancers in HIV-infected patientsHematologic toxicity in anal cancer patients during combined chemo-radiation: a radiation oncologist perspective.Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patientsDosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors.Efficacy and toxicity of chemoradiation in patients with anal cancer--a retrospective analysis.Technical aspects of radiation therapy for anal cancer.Anal squamous cell carcinoma: an evolution in disease and management.IMRT, RapidArc® and conformal radiotherapy in the treatment of tumours of the anal canal.RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canalInterstitial high-dose rate brachytherapy as boost for anal canal cancer.Radioluminescence characterization of in situ x-ray nanodosimeters: Potential real-time monitors and modulators of external beam radiation therapyRadiation therapy of anal canal cancer: from conformal therapy to volumetric modulated arc therapyClinical experience of SIB-IMRT in anal cancer and selective literature review.Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges.French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patientsIntensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivityImpact of facility volume on outcomes in patients with squamous cell carcinoma of the anal canal: Analysis of the National Cancer Data Base.Proposed genitalia contouring guidelines in anal cancer intensity-modulated radiotherapy.Long-term outcomes of chemoradiation for anal cancer patients.Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?Genital invasion or perigenital spread may pose a risk of marginal misses for Intensity Modulated Radiotherapy (IMRT) in anal cancerPredictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma.Intensity-Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal.Sphincter preservation in anal cancer: a brief review.Management of two cases of recurrent anal carcinoma.Acute gastrointestinal toxicity and tumor response with preoperative intensity modulated radiation therapy for rectal cancer.ACR Appropriateness Criteria®-Anal Cancer.Optimal treatment strategies for anal cancer.Anal cancer: current standards in care and recent changes in practice.A new plan quality index for dose painting radiotherapy.Advances in the Management of Anal Cancer.Intensity-modulated radiotherapy for squamous cell carcinoma of the anal canal: efficacy of a low daily dose to clinically negative regions.Reduced radiation dose for elective nodal irradiation in node-negative anal cancer: back to the roots?Efficacy and safety of helical tomotherapy with daily image guidance in anal canal cancer patients.Influence of radiation treatment technique on outcome and toxicity in anal cancer.Prevalence of patient-reported gastrointestinal symptoms and agreement with clinician toxicity assessments in radiation therapy for anal cancer.Lumbar-sacral bone marrow dose modeling for acute hematological toxicity in anal cancer patients treated with concurrent chemo-radiation.Concurrent paclitaxel, capecitabine, mitomycin C and pelvic radiation therapy for patients with squamous cell anal carcinoma.
P2860
Q26861496-F852660F-EA21-49A7-A33B-F191E15D7B62Q30235359-00215556-FBAA-49A7-80AC-C7A1CAF8EAFDQ33422634-6C291522-255E-4FD1-A3EE-D5725A9BA4E3Q33429717-4495FB33-CC33-4410-A94E-BE1A5A615F3DQ33431168-756673D8-C4FE-409C-97AE-ADCA35F22BEDQ33457264-881DED4A-FA6B-4936-B82A-318D3CC2CAF2Q33646367-4EB3D4FE-02C7-4631-B6AD-468ED16A9A73Q33820797-40A36BE7-D643-4939-AFCD-0C0E31486BEFQ34255528-E9C9CA21-E3DB-4BC9-8806-414C70079EFFQ34372829-AD8636A8-FB10-4F87-9B74-B849607FCDA7Q34478729-53BBA379-30D4-4084-B8C1-A092F9CF81B0Q34499551-BA34EDA5-0DBF-49DD-91CF-5CF2D099CFD9Q34558103-CCA6E7D2-2E6F-4365-ADF0-452FAAE8651EQ34584811-4D3E74DF-E909-4AF8-A092-D6692B7C5528Q34667668-D9E6DFB0-2A9E-4B9C-BC34-B6631C3CC040Q35850380-7D71423D-905B-4CEA-AC76-E6CEE81B80C3Q36009950-8AB3219B-BE92-4B2D-B17A-FE17203404C3Q36105656-ED1AA09E-84F4-4E18-98B2-A52AE7C8B8B5Q36115829-39B1502C-6709-4CAD-A6EE-2672762D03D1Q36235721-D95C47BC-7679-485E-BF5E-36B42EE32359Q36463914-26A47C09-F6B1-411B-905F-010BD4D38D27Q36621336-C8A8CEA6-2DD1-4245-9BC3-7E375C796D38Q36765574-C38C38E3-66C1-4D96-8328-EC93F4C4D0BDQ36770084-0CB07F86-4B04-4E5E-90D0-0EF2FFFCBE36Q36907276-1E96BC2B-CE51-48CD-B092-7E40DC4EE6E5Q37005884-710750AA-04FD-47D9-86AB-D47E184F761DQ37251305-62F6242C-21DD-4528-B90D-DF9445C90D79Q37362253-9E90A787-93D7-4974-92D8-CFE157245F40Q37584860-1F853654-A6F4-4DA6-BB03-F949EF1CC05BQ38227802-E13356F5-5012-44D9-935D-14A5E20A441EQ38315952-D0F4B530-0F7D-4707-B3A2-80B299BE790EQ38418854-AFF212FF-2EC3-4900-BC28-42B1C72D9CF2Q38746232-FF308C57-51F4-4D8B-B201-A5494FDAFD14Q38783988-018624CD-A4A1-46DC-A691-57FD48CADFDCQ38970764-06B381C2-8B36-47BB-BC99-BDA2C094FB2DQ40823548-55872ADF-03C8-47B0-80F0-42A2A46EB9C8Q47101467-1F6B01A3-92F3-4017-B513-FE8FA24852B3Q48106440-C811EF01-AC70-49B3-9FC8-6A7E42EFC6C4Q48244052-B6A1766C-2F84-4C8A-A6AB-4B369504F969Q48309176-3B8FB961-B99B-4D4F-AE55-A15A2981A1C9
P2860
Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Dose-painted intensity-modulat ...... icity and response to therapy.
@ast
Dose-painted intensity-modulat ...... icity and response to therapy.
@en
type
label
Dose-painted intensity-modulat ...... icity and response to therapy.
@ast
Dose-painted intensity-modulat ...... icity and response to therapy.
@en
prefLabel
Dose-painted intensity-modulat ...... icity and response to therapy.
@ast
Dose-painted intensity-modulat ...... icity and response to therapy.
@en
P2093
P1476
Dose-painted intensity-modulat ...... icity and response to therapy.
@en
P2093
David P Ryan
Eunice L Kwak
Henry K Tsai
John D Willins
John J Coen
Lawrence S Blaszkowsky
Lisa A Kachnic
Theodore S Hong
P304
P356
10.1016/J.IJROBP.2010.09.030
P407
P577
2010-11-20T00:00:00Z